GE Healthcare pairs up with Pharmadule to expand KUBio offering

By Vassia Barba contact

- Last updated on GMT

(GE Healthcare / The modules of the next KUBio facility on their way to Guangzhou, China)
(GE Healthcare / The modules of the next KUBio facility on their way to Guangzhou, China)

Related tags: Ge healthcare, GE Healthcare Life Sciences, Monoclonal antibodies, Viral vector, Gene therapy

GE Healthcare assigns Pharmadule Morimatsu to expand the offering of its ‘factory in a box’, known as KUBio, enabling the scale-up of biologics manufacture.

KUBio is a modular facility by GE Healthcare that was initially launched in 2012 for the manufacturing of monoclonal antibodies (mAbs), and was later expanded to support production of vaccines and viral vectors.

The facility is already adopted by several companies including JHL, Pfizer, and BeiGene.

In collaboration with Pharmadule Morimatsu, GE Healthcare is now in the process of installing a KUBio facility in Guangzhou, China, which is expected to “accelerate the accessibility of biotherapeutics on a global scale.”​ 

Under the collaboration, Pharmadule Morimatsu, which focuses on the design of modular facilities, will provide engineering design, construction, installation, and validation services, based on the platform’s proprietary design.

The company announced that it plans to have more modular facilities available for clients in 2020.

Michelle Stafford, GE Healthcare’s senior global product marketing leader, told us that the expansion supports the company’s plans to “address the needs of a large patient population, as well as the speed and quality”​ required in Asia, due to a rising market growth in the region – especially regarding the manufacture of biosimilars, mAbs and cell therapies.

Asked about interest shown in the expanded KUBio from clients, Joe Makowiecki, director of business development and enterprise solutions, replied: “We have had multiple customer conversations around not only the KUBio facility for BSL-1, but also the KUBio facility for BSL-2 and KUBio facility for Cell Therapy (CAR-T).”

Related news

Show more

Related products

Microsampling in Early Phase Drug Development

Microsampling in Early Phase Drug Development

Altasciences | 10-May-2022 | Technical / White Paper

Microsampling significantly lessens the volume of blood and plasma/serum that is collected and analyzed to determine circulating concentrations of therapeutic...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Partner with Experts in Precision Medicine

Partner with Experts in Precision Medicine

CellCarta | 17-Jan-2022 | Product Brochure

At CellCarta, we’re dedicated to working with our partners to further the limitless potential of precision medicine. Our broad technology offering is designed...

Related suppliers